Commonwealth of Pennsylvania Public School Empls Retrmt SYS Increases Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 287.2% in the first quarter, HoldingsChannel.com reports. The fund owned 31,674 shares of the company’s stock after purchasing an additional 23,494 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Immunocore were worth $955,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in Immunocore by 334.3% during the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after acquiring an additional 974,463 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Immunocore in the 4th quarter worth $20,305,000. Janus Henderson Group PLC bought a new position in Immunocore in the 4th quarter worth $15,734,000. Bellevue Group AG lifted its position in Immunocore by 14.5% during the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares in the last quarter. Finally, Tang Capital Management LLC lifted its position in Immunocore by 14.0% during the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after purchasing an additional 322,930 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Trading Up 1.4%

IMCR opened at $34.96 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The stock’s 50 day moving average price is $30.12 and its 200-day moving average price is $31.29. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -63.56 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. On average, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on IMCR. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, April 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday. Finally, Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $56.71.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.